clinical trials
-
NIH officials discuss agency’s Long COVID clinical trials, respond to critiques
“We understand the frustration and respect it completely,” said NIAID program officer and TLC leader Joseph Breen, when asked about the more than a year that’s gone between RECOVER-TLC trials’ announcement and enrolling participants.
-
Live blog: RECOVER-TLC third annual workshop shares updates on Long COVID clinical trials
Leading Long COVID scientists, government officials, and advocates are meeting today and tomorrow in Bethesda, Maryland for the third annual RECOVER-Treating Long COVID (TLC) workshop, hosted by the National Institutes of Health (NIH) and Foundation for the National Institutes of Health (FNIH). At a hotel near the NIH campus, attendees will hear updates on the…
-
Research updates, November 3
Multiple COVID-19 precautions during the Tokyo Olympic and Paralympic Games were effective in minimizing SARS-CoV-2 transmission, according to a new study in Eurosurveillance. Using retrospective epidemiological data, Japanese researchers found that spread was very low during the games, as most cases occurred during arrival or mandatory quarantines before the games.
-
Novel drug bezisterim plans for further study in Long COVID. Here’s how the phase 2 trial came together.
Novel anti-inflammatory drug shows early promise in treating Long COVID cognitive symptoms, fatigue, PEM. The study looked at multiple endpoints and consulted with people living with the disease.
-
Research updates, October 27
Low-dose prednisolone may temporarily reduce some “symptom severity” of Long COVID, according to a new study in eClinicalMedicine. German researchers evaluated the drug, a corticosteroid that reduces inflammation and is used to treat a broad range of conditions, alongside some B vitamins, in the phase 3 clinical trial.
-
Research updates, October 20
A large Long COVID review found mechanisms of “accelerated biological aging” in young adults. The review was published in Ageing Research Reviews and synthesized 110 mechanistic and epidemiological Long COVID studies on adults ages 25–55.
-
Research updates, October 13
A new study found COVID-19 was linked to a significant increase in dementia in older people with type 2 diabetes. The retrospective study published in Frontiers in Aging Neuroscience included a cohort of nearly half a million people with documented SARS-C0V-2 infections.
-
Biological pathways and mechanistic trials centered at new Long COVID conference in Amsterdam
Researchers, clinicians, and advocates gathered for the inaugural conference of the International Society for Long COVID and Post-Acute Infection Syndromes in the Netherlands in late August. The four-day event featured hundreds of presentations and posters about trials and disease mechanisms.
-
Research updates, September 29
A small clinical trial found Remdesivir was safe for people with Long COVID and that some exploratory results warrant a larger trial. The U.K. trial, which included 73 participants who took a five day course of the intravenous antiviral COVID-19 drug, was published in Oxford Open Immunology.
-
People with Long COVID demand pause of McMaster University clinical trial
The trial, run by researchers at McMaster University in Canada, is testing the Lightning Process, a pseudoscientific mind-body program that outside experts have heavily criticized.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance